Articles
03.08.2022
EU Joint HTA: How will EUNetHTA balance contrastin...

Our Market Access analysts summarise the EUnetHTA draft scoping process and provide considerations a...

Read more
Articles
28.06.2022
EU Joint HTA: How will EUNetHTA balance contrastin...

The EUNetHTA recently published its draft scoping guidance which outlines how the contrasting decisi...

Read more
Insider Insights
23.06.2022
NICE publish their new real world evidence framewo

NICE have been clear that this framework should not be interpreted as minimum standards for real-wor...

Read more
Articles
22.06.2022
EU Joint HTA: How should manufacturers adapt to th...

EUnetHTA and the EU Joint HTA Process EUnetHTA was established in 2006 to facilitate information sha...

Read more
Articles
21.06.2022
Seeking early advice from the EMA and multiple HTA...

Introduction Achieving access to patients for innovative treatments is becoming a significant challe...

Read more
News
15.06.2022
PMA Insights: Week 24

We summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...

Read more
Insider Insights
09.06.2022
UK launch of innovative medicines fund

Through the new fund, £340 million is to be made available to purchase promising, potentially life-...

Read more
News
01.06.2022
PMA Insights: Week 22

We summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...

Read more
News
18.05.2022
PMA Insights: Week 20

We summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...

Read more
Articles
07.12.2021
What are the 5 Pricing & Market Access trends ...

Our experts provide an overview of the five key trends that could shape the pricing and market acces...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.